{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:10:26Z","timestamp":1793859026545,"version":"4.6.1"},"reference-count":143,"publisher":"Zhejiang University Press","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1631\/jzus.b1400131","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T23:29:11Z","timestamp":1413329351000},"page":"845-863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":192,"title":["Therapeutic radionuclides in nuclear medicine: current and future prospects","\u6838\u533b\u5b66\u653e\u5c04\u6027\u6838\u7d20\u6cbb\u7597\u7684\u7814\u7a76\u73b0\u72b6\u53ca\u524d\u666f"],"prefix":"10.1631","volume":"15","author":[{"given":"Chai-Hong","family":"Yeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu-hua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan-Hoong","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"635","published-online":{"date-parts":[[2014,10,16]]},"reference":[{"issue":"3Suppl.2","key":"3716_CR1","first-page":"27","volume":"20","author":"D Ackery","year":"1993","unstructured":"Ackery, D., Yardley, J., 1993. Radionuclide-targeted therapy for the management of metastatic bone pain. Semin. Oncol., 20(3 Suppl. 2):27\u201331.","journal-title":"Semin. Oncol."},{"issue":"14","key":"3716_CR2","first-page":"1925","volume":"16","author":"C Alberti","year":"2012","unstructured":"Alberti, C., 2012. From molecular imaging in preclinical\/clinical oncology to theranostic applications in targeted tumor therapy. Eur. Rev. Med. Pharmacol. Sci., 16(14): 1925\u20131933.","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"3716_CR3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11864-002-0027-y","volume":"3","author":"T Alcindor","year":"2002","unstructured":"Alcindor, T., Witzig, T.E., 2002. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin\u2019s lymphoma. Curr. Treat. Options Oncol., 3(4):275\u2013282. [doi:10.1007\/s11864-002-0027-y]","journal-title":"Curr. Treat. Options Oncol."},{"issue":"4","key":"3716_CR4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF01451005","volume":"17","author":"A Alonso-Ruiz","year":"1998","unstructured":"Alonso-Ruiz, A., Perez-Ruiz, F., Calabozo, M., et al., 1998. Efficacy of radiosynovectomy of the knee in rheumatoid arthritis: evaluation with magnetic resonance imaging. Clin. Rheumatol., 17(4):277\u2013281. [doi:10.1007\/BF01451005]","journal-title":"Clin. Rheumatol."},{"issue":"11","key":"3716_CR5","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1586\/14737140.7.11.1517","volume":"7","author":"P Anderson","year":"2007","unstructured":"Anderson, P., Nunez, R., 2007. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev. Anticancer Ther., 7(11):1517\u20131527. [doi:10.1586\/14737140.7.11.1517]","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"4","key":"3716_CR6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2298\/VSP1104341A","volume":"68","author":"N Arslan","year":"2011","unstructured":"Arslan, N., Emi, M., Alagoz, E., et al., 2011. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center. Vojnosanit. Pregl., 68(4):341\u2013348. [doi:10.2298\/VSP1104341A]","journal-title":"Vojnosanit. Pregl."},{"issue":"4","key":"3716_CR7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0969-8043(97)00039-0","volume":"49","author":"HL Atkins","year":"1998","unstructured":"Atkins, H.L., 1998. Overview of nuclides for bone pain palliation. Appl. Radiat. Isot., 49(4):277\u2013283. [doi:10.1016\/S0969-8043(97)00039-0]","journal-title":"Appl. Radiat. Isot."},{"issue":"12","key":"3716_CR8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-006-0148-4","volume":"55","author":"I Azinovic","year":"2006","unstructured":"Azinovic, I., DeNardo, G.L., Lamborn, K.R., et al., 2006. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol. Immunother., 55(12):1451\u20131458. [doi: 10.1007\/s00262-006-0148-4]","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"3716_CR9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","volume":"36","author":"M Bartolomei","year":"2009","unstructured":"Bartolomei, M., Bodei, L., de Cicco, C., et al., 2009. Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. Eur. J. Nucl. Med. Mol. Imaging, 36(9):1407\u20131416. [doi:10.1007\/s00259-009-1115-z]","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"3716_CR10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7150\/thno.3645","volume":"2","author":"RP Baum","year":"2012","unstructured":"Baum, R.P., Kulkarni, H.R., 2012. THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy\u2014the bad Berka experience. Theranostics, 2(5):437\u2013447. [doi:10.7150\/thno.3645]","journal-title":"Theranostics"},{"key":"3716_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","volume":"66","author":"N Bertrand","year":"2014","unstructured":"Bertrand, N., Wu, J., Xu, X., et al., 2014. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev., 66:2\u201325. [doi:10.1016\/j.addr.2013.11.009]","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"3716_CR12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF03345728","volume":"32","author":"L Bodei","year":"2009","unstructured":"Bodei, L., Ferone, D., Grana, C.M., et al., 2009. Peptide receptor therapies in neuroendocrine tumors. J. Endocrinol. Invest., 32(4):360\u2013369. [doi:10.1007\/BF03345728]","journal-title":"J. Endocrinol. Invest."},{"issue":"10","key":"3716_CR13","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-05-2804","volume":"12","author":"SS Brack","year":"2006","unstructured":"Brack, S.S., Silacci, M., Birchler, M., et al., 2006. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin. Cancer Res., 12(10): 3200\u20133208. [doi:10.1158\/1078-0432.CCR-05-2804]","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"3716_CR14","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/sj.bjc.6603166","volume":"94","author":"F Buchegger","year":"2006","unstructured":"Buchegger, F., Antonescu, C., Delaloye, A.B., et al., 2006. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin\u2019s lymphoma. Br. J. Cancer, 94(12):1770\u20131776. [doi:10.1038\/sj.bjc.6603166]","journal-title":"Br. J. Cancer"},{"issue":"2","key":"3716_CR15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/108497802753773775","volume":"17","author":"I Buchmann","year":"2002","unstructured":"Buchmann, I., Bunjes, D., Kotzerke, J., et al., 2002. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother. Radiopharm., 17(2):151\u2013163. [doi:10.1089\/108497802753773775]","journal-title":"Cancer Biother. Radiopharm."},{"issue":"5","key":"3716_CR16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jso.23196","volume":"106","author":"JA Carrasquillo","year":"2012","unstructured":"Carrasquillo, J.A., Pandit-Taskar, N., Chen, C.C., 2012. Radionuclide therapy of adrenal tumors. J. Surg. Oncol., 106(5):632\u2013642. [doi:10.1002\/jso.23196]","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"3716_CR17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10967-013-2823-1","volume":"299","author":"R Chakravarty","year":"2014","unstructured":"Chakravarty, R., Dash, A., 2014. Nanomaterial-based adsorbents: the prospect of developing new generation radionuclide generators to meet future research and clinical demands. J. Radioanal. Nucl. Chem., 299(1):741\u2013757. [doi:10.1007\/s10967-013-2823-1]","journal-title":"J. Radioanal. Nucl. Chem."},{"issue":"4","key":"3716_CR18","first-page":"2719","volume":"25","author":"CH Chang","year":"2005","unstructured":"Chang, C.H., Tsai, L.C., Chen, S.T., et al., 2005. Radio-immunotherapy and apoptotic induction on CK19-overexpressing human cervical carcinoma cells with Re-188-mAbCx-99. Anticancer Res., 25(4):2719\u20132728.","journal-title":"Anticancer Res."},{"issue":"7","key":"3716_CR19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0969-8051(01)00244-X","volume":"28","author":"FD Chen","year":"2001","unstructured":"Chen, F.D., Hsieh, B.T., Wang, H.E., et al., 2001. Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals. Nucl. Med. Biol., 28(7):835\u2013844. [doi:10.1016\/S0969-8051(01)00244-X]","journal-title":"Nucl. Med. Biol."},{"issue":"7","key":"3716_CR20","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.2005.06.108","volume":"23","author":"S Chen","year":"2005","unstructured":"Chen, S., Yu, L., Jiang, C., et al., 2005. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol., 23(7):1538\u20131547. [doi:10.1200\/JCO.2005.06.108]","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"3716_CR21","first-page":"623","volume":"92","author":"WL Chen","year":"1993","unstructured":"Chen, W.L., Guan, S.I., Huang, W.S., 1993. Radioiodine I-131 therapy in the management of differentiated thyroid carcinoma: a review of 202 patients. J. Formos. Med. Assoc., 92(7):623\u2013631. [doi:10.1016\/j.ijrobp.2005.12.034]","journal-title":"J. Formos. Med. Assoc."},{"issue":"2","key":"3716_CR22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijrobp.2005.12.034","volume":"65","author":"ZN Chen","year":"2006","unstructured":"Chen, Z.N., Mi, L., Xu, J., et al., 2006. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical Phase I\/II trials. Int. J. Radiat. Oncol. Biol. Phys., 65(2):435\u2013444. [doi:10.1016\/j.ijrobp.2005.12.034]","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"3716_CR23","first-page":"431","volume":"55","author":"S Chiacchio","year":"2011","unstructured":"Chiacchio, S., Mazzarri, S., Lorenzoni, A., et al., 2011. Radionuclide therapy and integrated protocols for bone metastases. Q. J. Nucl. Med. Mol. Imaging, 55(4):431\u2013447.","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"3716_CR24","doi-asserted-by":"crossref","first-page":"B12","DOI":"10.1007\/s00259-002-1058-0","volume":"30","author":"G Clunie","year":"2003","unstructured":"Clunie, G., Fischer, M., 2003. EANM procedure guidelines for radiosynovectomy. Eur. J. Nucl. Med. Mol. Imaging, 30(3):B12\u2013B16. [doi:10.1007\/s00259-002-1058-0]","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"3716_CR25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s002590050462","volume":"26","author":"M Cremonesi","year":"1999","unstructured":"Cremonesi, M., Ferrari, M., Zoboli, S., et al., 1999. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC. Eur. J. Nucl. Med. Mol. Imaging, 26(8):877\u2013886. [doi:10.1007\/s002590050462]","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"3716_CR26","first-page":"1467","volume":"47","author":"M Cremonesi","year":"2006","unstructured":"Cremonesi, M., Ferrari, M., Bodei, L., et al., 2006. Dosimetry in peptide radionuclide receptor therapy: a review. J. Nucl. Med., 47(9):1467\u20131475.","journal-title":"J. Nucl. Med."},{"issue":"4","key":"3716_CR27","first-page":"e45","volume":"3","author":"BK Das","year":"2007","unstructured":"Das, B.K., 2007. Role of radiosynovectomy in the treatment of rheumatoid arthritis and hemophilic arthropathies. Biomed. Imaging Interv. J., 3(4):e45. [doi:10.2349\/biij.3.4.e45]","journal-title":"Biomed. Imaging Interv. J."},{"issue":"1","key":"3716_CR28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nucmedbio.2012.09.007","volume":"40","author":"T Das","year":"2013","unstructured":"Das, T., Pillai, M.R., 2013. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl. Med. Biol., 40(1):23\u201332. [doi:10.1016\/j.nucmedbio.2012.09.007]","journal-title":"Nucl. Med. Biol."},{"issue":"3","key":"3716_CR29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/18744710113066660023","volume":"6","author":"A Dash","year":"2013","unstructured":"Dash, A., Knapp, F.F., Pillai, M.R., 2013. Targeted radionuclide therapy\u2014an overview. Curr. Radiopharm., 6(3): 152\u2013180. [doi:10.2174\/18744710113066660023]","journal-title":"Curr. Radiopharm."},{"issue":"9","key":"3716_CR30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"ME Davis","year":"2008","unstructured":"Davis, M.E., Chen, Z.G., Shin, D.M., 2008. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 7(9):771\u2013782. [doi:10.1038\/nrd2614]","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"3716_CR31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","volume":"32","author":"M Jong de","year":"2002","unstructured":"de Jong, M., Valkema, R., Jamar, F., et al., 2002. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin. Nucl. Med., 32(2): 133\u2013140. [doi:10.1053\/snuc.2002.31027]","journal-title":"Semin. Nucl. Med."},{"issue":"S1","key":"3716_CR32","first-page":"13S","volume":"46","author":"M Jong de","year":"2005","unstructured":"de Jong, M., Breeman, W.A., Valkema, R., et al., 2005. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J. Nucl. Med., 46(S1):13S\u201317S.","journal-title":"J. Nucl. Med."},{"issue":"5","key":"3716_CR33","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1538-7836.2011.04246.x","volume":"9","author":"H Corte-Rodriguez de la","year":"2011","unstructured":"de la Corte-Rodriguez, H., Rodriguez-Merchan, E.C., Jimenez-Yuste, V., 2011. Radiosynovectomy in hemophilia: quantification of its effectiveness through the assessment of 10 articular parameters. J. Thromb. Haemost., 9(5): 928\u2013935. [doi:10.1111\/j.1538-7836.2011.04246.x]","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"3716_CR34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cbr.1998.13.239","volume":"13","author":"GL DeNardo","year":"1998","unstructured":"DeNardo, G.L., DeNardo, S.J., Lamborn, K.R., et al., 1998. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother. Radiopharm., 13(4):239\u2013254. [doi:10.1089\/cbr.1998.13.239]","journal-title":"Cancer Biother. Radiopharm."},{"issue":"11","key":"3716_CR35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/BF00173494","volume":"20","author":"E Deutsch","year":"1993","unstructured":"Deutsch, E., Brodack, J.W., Deutsch, K.F., 1993. Radiation synovectomy revisited. Eur. J. Nucl. Med., 20(11): 1113\u20131127. [doi:10.1007\/BF00173494]","journal-title":"Eur. J. Nucl. Med."},{"issue":"2","key":"3716_CR36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/archinte.1960.03820020034006","volume":"106","author":"J Domnitz","year":"1960","unstructured":"Domnitz, J., Hurd, H.F., Goldzieher, J.W., 1960. The evaluation of I-131 therapy of Graves\u2019 disease. Reliability and prognostic value of chemical and radioactive iodine studies. Arch. Intern. Med., 106(2):194\u2013204. [doi:10.1001\/archinte.1960.03820020034006]","journal-title":"Arch. Intern. Med."},{"key":"3716_CR37","volume-title":"Holland-Frei Cancer Medicine","author":"WK Donald","year":"2003","unstructured":"Donald, W.K., Raphael, E.P., Ralph, R.W., et al., 2003. Holland-Frei Cancer Medicine. Hamilton, BC Decker."},{"issue":"1","key":"3716_CR38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2005.07.035","volume":"239","author":"IH El-Sayed","year":"2006","unstructured":"El-Sayed, I.H., Huang, X., El-Sayed, M.A., 2006. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett., 239(1):129\u2013135. [doi:10.1016\/j.canlet.2005.07.035]","journal-title":"Cancer Lett."},{"issue":"4","key":"3716_CR39","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.3390\/cancers3043838","volume":"3","author":"D Ersahin","year":"2011","unstructured":"Ersahin, D., Doddamane, I., Cheng, D., 2011. Targeted radionuclide therapy. Cancers, 3(4):3838\u20133855. [doi:10.3390\/cancers3043838]","journal-title":"Cancers"},{"issue":"11","key":"3716_CR40","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2967\/jnumed.112.107482","volume":"53","author":"S Ezziddin","year":"2012","unstructured":"Ezziddin, S., Meyer, C., Kahancova, S., et al., 2012. 90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy. J. Nucl. Med., 53(11): 1663\u20131669. [doi:10.2967\/jnumed.112.107482]","journal-title":"J. Nucl. Med."},{"issue":"2","key":"3716_CR41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/156720107780362302","volume":"4","author":"S Ferguson","year":"2007","unstructured":"Ferguson, S., Lesniak, M.S., 2007. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr. Drug Deliv., 4(2):169\u2013180. [doi:10.2174\/156720107780362302]","journal-title":"Curr. Drug Deliv."},{"issue":"3","key":"3716_CR42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc1566","volume":"5","author":"M Ferrari","year":"2005","unstructured":"Ferrari, M., 2005. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer, 5(3):161\u2013171. [doi:10.1038\/nrc1566]","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"3716_CR43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1078\/0939-3889-00291","volume":"16","author":"G Flux","year":"2006","unstructured":"Flux, G., Bardies, M., Monsieurs, M., et al., 2006. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z. Med. Phys., 16(1):47\u201359.","journal-title":"Z. Med. Phys."},{"issue":"1B","key":"3716_CR44","first-page":"703","volume":"26","author":"F Forrer","year":"2006","unstructured":"Forrer, F., Waldherr, C., Maecke, H.R., et al., 2006. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res., 26(1B): 703\u2013707.","journal-title":"Anticancer Res."},{"issue":"1","key":"3716_CR45","first-page":"7","volume":"36","author":"E Forssell-Aronsson","year":"1995","unstructured":"Forssell-Aronsson, E., Fjalling, M., Nilsson, O., et al., 1995. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J. Nucl. Med., 36(1):7\u201312.","journal-title":"J. Nucl. Med."},{"issue":"12","key":"3716_CR46","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s002590100628","volume":"28","author":"GJ Forster","year":"2001","unstructured":"Forster, G.J., Engelbach, M.J., Brockmann, J.J., et al., 2001. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide. Eur. J. Nucl. Med., 28(12):1743\u20131750. [doi:10.1007\/s002590100628]","journal-title":"Eur. J. Nucl. Med."},{"issue":"1","key":"3716_CR47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1586\/14737140.4.1.18","volume":"4","author":"JW Friedberg","year":"2004","unstructured":"Friedberg, J.W., Fisher, R.I., 2004. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin\u2019s lymphoma. Expert Rev. Anticancer Ther., 4(1):18\u201326. [doi:10.1586\/14737140.4.1.18]","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"19\u201320","key":"3716_CR48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s10354-012-0128-6","volume":"162","author":"M Gabriel","year":"2012","unstructured":"Gabriel, M., 2012. Radionuclide therapy beyond radioiodine. Wien Med. Wochenschr., 162(19\u201320):430\u2013439. [doi:10.1007\/s10354-012-0128-6]","journal-title":"Wien Med. Wochenschr."},{"issue":"1","key":"3716_CR49","first-page":"78","volume":"45","author":"F Giammarile","year":"2001","unstructured":"Giammarile, F., Mognetti, T., Resche, I., 2001. Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q. J. Nucl. Med., 45(1):78\u201383.","journal-title":"Q. J. Nucl. Med."},{"issue":"7","key":"3716_CR50","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1021\/nl070610y","volume":"7","author":"AM Gobin","year":"2007","unstructured":"Gobin, A.M., Lee, M.H., Halas, N.J., et al., 2007. Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett., 7(7):1929\u20131934. [doi:10.1021\/nl070610y]","journal-title":"Nano Lett."},{"issue":"4","key":"3716_CR51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<945::AID-CNCR24>3.0.CO;2-I","volume":"85","author":"PW Grigsby","year":"1999","unstructured":"Grigsby, P.W., Baglan, K., Siegel, B.A., 1999. Surveillance of patients to detect recurrent thyroid carcinoma. Cancer, 85(4):945\u2013951. [doi:10.1002\/(SICI)1097-0142(19990215)85:4\u2329945::AID-CNCR24\u232a3.0.CO;2-I]","journal-title":"Cancer"},{"issue":"4","key":"3716_CR52","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.clon.2011.12.003","volume":"24","author":"KY Gulenchyn","year":"2012","unstructured":"Gulenchyn, K.Y., Yao, X., Asa, S.L., et al., 2012. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin. Oncol., 24(4):294\u2013308. [doi:10.1016\/j.clon.2011.12.003]","journal-title":"Clin. Oncol."},{"issue":"8","key":"3716_CR53","first-page":"1216","volume":"42","author":"KA Hamacher","year":"2001","unstructured":"Hamacher, K.A., Den, R.B., Den, E.I., et al., 2001. Cellular dose conversion factors for \u03b1-particle-emitting radionuclides of interest in radionuclide therapy. J. Nucl. Med., 42(8):1216\u20131221.","journal-title":"J. Nucl. Med."},{"key":"3716_CR54","first-page":"268479","volume":"2014","author":"S Han","year":"2014","unstructured":"Han, S., Jin, G., Wang, L., et al., 2014. The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy. J. Immunol. Res., 2014:268479. [doi:10.1155\/2014\/268479]","journal-title":"J. Immunol. Res."},{"issue":"6","key":"3716_CR55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2217\/fon.12.58","volume":"8","author":"A Hdeib","year":"2012","unstructured":"Hdeib, A., Sloan, A., 2012. Targeted radioimmunotherapy: the role of 131I-chTNT-1\/B mAb (Cotara) for treatment of high-grade gliomas. Future Oncol., 8(6):659\u2013669. [doi:10.2217\/fon.12.58]","journal-title":"Future Oncol."},{"issue":"47","key":"3716_CR56","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.3748\/wjg.v19.i47.9104","volume":"19","author":"Q He","year":"2013","unstructured":"He, Q., Lu, W.S., Liu, Y., et al., 2013. 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma. World J. Gastroenterol., 19(47): 9104\u20139110. [doi:10.3748\/wjg.v19.i47.9104]","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"3716_CR57","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bjc.1993.349","volume":"68","author":"V Hird","year":"1993","unstructured":"Hird, V., Maraveyas, A., Snook, D., et al., 1993. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer, 68(2):403\u2013406. [doi:10.1038\/bjc.1993.349]","journal-title":"Br. J. Cancer"},{"issue":"6","key":"3716_CR58","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF02258432","volume":"18","author":"CA Hoefnagel","year":"1991","unstructured":"Hoefnagel, C.A., 1991. Radionuclide therapy revisited. Eur. J. Nucl. Med., 18(6):408\u2013431. [doi:10.1007\/BF02258432]","journal-title":"Eur. J. Nucl. Med."},{"issue":"2","key":"3716_CR59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF03164831","volume":"12","author":"CA Hoefnagel","year":"1998","unstructured":"Hoefnagel, C.A., 1998. Radionuclide cancer therapy. Ann. Nucl. Med., 12(2):61\u201370. [doi:10.1007\/BF03164831]","journal-title":"Ann. Nucl. Med."},{"issue":"4","key":"3716_CR60","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00256489","volume":"13","author":"CA Hoefnagel","year":"1987","unstructured":"Hoefnagel, C.A., den Hartog Jager, F.C., Taal, B.G., et al., 1987. The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur. J. Nucl. Med., 13(4):187\u2013191. [doi:10.1007\/BF00256489]","journal-title":"Eur. J. Nucl. Med."},{"issue":"5","key":"3716_CR61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nantod.2009.07.001","volume":"4","author":"H Hong","year":"2009","unstructured":"Hong, H., Zhang, Y., Sun, J., et al., 2009. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nanotoday, 4(5):399\u2013413. [doi:10.1016\/j.nantod.2009.07.001]","journal-title":"Nanotoday"},{"issue":"4","key":"3716_CR62","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","volume":"23","author":"SJ Horning","year":"2005","unstructured":"Horning, S.J., Younes, A., Jain, V., et al., 2005. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol., 23(4):712\u2013719. [doi:10.1200\/JCO.2005.07.040]","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"3716_CR63","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1148\/radiology.172.3.2549567","volume":"172","author":"S Houle","year":"1989","unstructured":"Houle, S., Yip, T.K., Shepherd, F.A., et al., 1989. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology, 172(3):857\u2013860. [doi:10.1148\/radiology.172.3.2549567]","journal-title":"Radiology"},{"issue":"6","key":"3716_CR64","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1021\/ja057254a","volume":"128","author":"X Huang","year":"2006","unstructured":"Huang, X., El-Sayed, I.H., Qian, W., et al., 2006. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J. Am. Chem. Soc., 128(6):2115\u20132120. [doi:10.1021\/ja057254a]","journal-title":"J. Am. Chem. Soc."},{"key":"3716_CR65","volume-title":"Proceedings of an International Symposium Organized by the IAEA, Vienna, Austria","author":"International Atomic Energy Agency IAEA","year":"2007","unstructured":"International Atomic Energy Agency (IAEA), 2007. Trends in radiopharmaceuticals (ISTR-2005). Proceedings of an International Symposium Organized by the IAEA, Vienna, Austria."},{"key":"3716_CR66","first-page":"473","volume-title":"Technical Report Series","author":"International Atomic Energy Agency IAEA","year":"2012","unstructured":"International Atomic Energy Agency (IAEA), 2012. Nuclear data for production of therapeutic radionuclides. Technical Report Series 473."},{"key":"3716_CR67","volume-title":"Nuclear Medicine Therapy","author":"FE Janet","year":"2007","unstructured":"IAEA, Vienna, Austria. Janet, F.E., Winfried, B., 2007. Nuclear Medicine Therapy. Informa Healthcare USA, New York."},{"issue":"1","key":"3716_CR68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1568014024606502","volume":"1","author":"WU Kampen","year":"2002","unstructured":"Kampen, W.U., Brenner, W., Czech, N., et al., 2002. Intraarticular application of unsealed \u03b2-emitting radionuclides in the treatment course of inflammatory joint diseases. Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents, 1(1): 77\u201387. [doi:10.2174\/156801402460 6502]","journal-title":"Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents"},{"issue":"S1","key":"3716_CR69","first-page":"4S","volume":"46","author":"AI Kassis","year":"2005","unstructured":"Kassis, A.I., Adelstein, S.J., 2005. Radiobiologic principles in radionuclide therapy. J. Nucl. Med., 46(S1):4S\u201312S.","journal-title":"J. Nucl. Med."},{"issue":"4","key":"3716_CR70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0969-8043(97)00043-2","volume":"49","author":"FFR Knapp Jr.","year":"1998","unstructured":"Knapp, F.F.R.Jr., Mirzadeh, S., Beets, A.L., et al., 1998. Reactor-produced radioisotopes from ORNL for bone pain palliation. Appl. Radiat. Isot., 49(4):309\u2013315. [doi:10.1016\/S0969\u20138043(97)00043\u20132","journal-title":"Appl. Radiat. Isot."},{"issue":"7","key":"3716_CR71","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.tibtech.2013.04.007","volume":"31","author":"GC Krijger","year":"2013","unstructured":"Krijger, G.C., Ponsard, B., Harfensteller, M., et al., 2013. The necessity of nuclear reactors for targeted radionuclide therapies. Trends Biotechnol., 31(7):390\u2013396. [doi:10.1016\/j.tibtech.2013.04.007]","journal-title":"Trends Biotechnol."},{"issue":"1","key":"3716_CR72","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1477-7819-9-86","volume":"9","author":"ON Kucuk","year":"2011","unstructured":"Kucuk, O.N., Soydal, C., Lacin, S., et al., 2011. Selective intraarterial radionuclide therapy with yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors. World J. Surg. Oncol., 9(1):86. [doi:10.1186\/1477-7819-9-86]","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"3716_CR73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4318\/tjg.2011.0164","volume":"22","author":"S Lacin","year":"2011","unstructured":"Lacin, S., Kucuk, O., Oz, I., et al., 2011. Selective intra-arterial Y-90 microsphere therapy in hemangioendothelioma. Turk. J. Gastroenterol., 22(1):89\u201392.","journal-title":"Turk. J. Gastroenterol."},{"issue":"5","key":"3716_CR74","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00002512-199711050-00007","volume":"11","author":"HM Lamb","year":"1997","unstructured":"Lamb, H.M., Faulds, D., 1997. Samarium 153Sm lexidronam. Drugs Aging, 11(5):413\u2013418. [doi:10.2165\/00002512-199711050-00007]","journal-title":"Drugs Aging"},{"issue":"4","key":"3716_CR75","first-page":"484","volume":"73","author":"B Lambert","year":"2010","unstructured":"Lambert, B., van Vlierberghe, H., Troisi, R., et al., 2010. Radionuclide therapy for hepatocellular carcinoma. Acta Gastroenterol. Belg., 73(4):484\u2013488.","journal-title":"Acta Gastroenterol. Belg."},{"issue":"16","key":"3716_CR76","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","volume":"10","author":"JP Leonard","year":"2004","unstructured":"Leonard, J.P., Coleman, M., Ketas, J.C., et al., 2004. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin\u2019s lymphoma: Phase I\/II clinical trial results. Clin. Cancer Res., 10(16):5327\u20135334. [doi: 10.1158\/1078-0432.CCR-04-0294]","journal-title":"Clin. Cancer Res."},{"issue":"S1","key":"3716_CR77","first-page":"38S","volume":"46","author":"VJ Lewington","year":"2005","unstructured":"Lewington, V.J., 2005. Bone-seeking radionuclides for therapy. J. Nucl. Med., 46(S1):38S\u201347S.","journal-title":"J. Nucl. Med."},{"issue":"3","key":"3716_CR78","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3171\/jns.2004.100.3.0472","volume":"100","author":"Z Lidar","year":"2004","unstructured":"Lidar, Z., Mardor, Y., Jonas, T., et al., 2004. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I\/II clinical study. J. Neurosurg., 100(3):472\u2013479. [doi:10.3171\/jns.2004.100.3.0472]","journal-title":"J. Neurosurg."},{"issue":"10","key":"3716_CR79","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1007\/s00296-011-2143-0","volume":"32","author":"K Liepe","year":"2012","unstructured":"Liepe, K., 2012. Efficacy of radiosynovectomy in rheumatoid arthritis. Rheumatol. Int., 32(10):3219\u20133224. [doi:10.1007\/s00296-011-2143-0]","journal-title":"Rheumatol. Int."},{"issue":"5","key":"3716_CR80","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12149-011-0467-1","volume":"25","author":"K Liepe","year":"2011","unstructured":"Liepe, K., Zaknun, J.J., Padhy, A., et al., 2011. Radiosynovectomy using yttrium-90, phosphorus-32 or rhenium-188 radiocolloids versus corticoid instillation for rheumatoid arthritis of the knee. Ann. Nucl. Med., 25(5): 317\u2013323. [doi:10.1007\/s12149-011-0467-1]","journal-title":"Ann. Nucl. Med."},{"issue":"27","key":"3716_CR81","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1200\/JCO.2005.18.622","volume":"23","author":"T Liersch","year":"2005","unstructured":"Liersch, T., Meller, J., Kulle, B., et al., 2005. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J. Clin. Oncol., 23(27):6763\u20136770. [doi:10.1200\/JCO.2005.18.622]","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"3716_CR82","doi-asserted-by":"crossref","first-page":"26","DOI":"10.11106\/jkta.2013.6.1.26","volume":"6","author":"I Lim","year":"2013","unstructured":"Lim, I., 2013. Image-based dosimetry of radionuclide therapy. J. Korean Thyroid Assoc., 6(1):26\u201333. [doi:10.11106\/jkta.2013.6.1.26]","journal-title":"J. Korean Thyroid Assoc."},{"key":"3716_CR83","volume-title":"X-rays and Radium in the Treatment of Diseases of the Skin","author":"GM MacKee","year":"1921","unstructured":"MacKee, G.M., 1921. X-rays and Radium in the Treatment of Diseases of the Skin. Lea & Febiger, New York."},{"issue":"6","key":"3716_CR84","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2967\/jnumed.110.084236","volume":"52","author":"HR Maecke","year":"2011","unstructured":"Maecke, H.R., Reubi, J.C., 2011. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J. Nucl. Med., 52(6):841\u2013844. [doi:10.2967\/jnumed.110.084236]","journal-title":"J. Nucl. Med."},{"issue":"S3","key":"3716_CR85","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/1097-0142(19940201)73:3+<1067::AID-CNCR2820731346>3.0.CO;2-#","volume":"73","author":"A Maraveyas","year":"1994","unstructured":"Maraveyas, A., Snook, D., Hird, V., et al., 1994. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer, 73(S3): 1067\u20131075. [doi:10.1002\/1097-0142(19940201)73:3+\u23291067::AID-CNCR2820731346\u232a3.0.CO;2-#]","journal-title":"Cancer"},{"issue":"6","key":"3716_CR86","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrd1413","volume":"3","author":"DE Milenic","year":"2004","unstructured":"Milenic, D.E., Brady, E.D., Brechbiel, M.W., 2004. Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discov., 3(6):488\u2013499. [doi:10.1038\/nrd1413]","journal-title":"Nat. Rev. Drug Discov."},{"issue":"36","key":"3716_CR87","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.2174\/138161206779026317","volume":"12","author":"A Mitra","year":"2006","unstructured":"Mitra, A., Nan, A., Line, B.R., et al., 2006. Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr. Pharm. Des., 12(36):4729\u20134749. [doi:10.2174\/138161206779026317]","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"3716_CR88","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2516.2006.01424.x","volume":"13","author":"SM Mortazavi","year":"2007","unstructured":"Mortazavi, S.M., Asadollahi, S., Farzan, M., et al., 2007. 32P colloid radiosynovectomy in treatment of chronic haemophilic synovitis: Iran experience. Haemophilia, 13(2): 182\u2013188. [doi:10.1111\/j.1365-2516.2006.01424.x]","journal-title":"Haemophilia"},{"key":"3716_CR89","volume-title":"Long term needs for nuclear data development: summary report of the advisory group meeting","author":"DW Muir","year":"2001","unstructured":"Muir, D.W., Herman, M., 2001. Long term needs for nuclear data development: summary report of the advisory group meeting. International Atomic Energy Agency, Vienna, Austria."},{"issue":"1","key":"3716_CR90","first-page":"25","volume":"16","author":"M Mumtaz","year":"2009","unstructured":"Mumtaz, M., Lin, L.S., Hui, K.C., et al., 2009. Radioiodine I-131 for the therapy of Graves\u2019 disease. Malays. J. Med. Sci., 16(1):25\u201333.","journal-title":"Malays. J. Med. Sci."},{"issue":"7","key":"3716_CR91","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","volume":"89","author":"Y Najean","year":"1997","unstructured":"Najean, Y., Rain, J.D., 1997a. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood, 89(7):2319\u20132327.","journal-title":"Blood"},{"issue":"1","key":"3716_CR92","first-page":"6","volume":"34","author":"Y Najean","year":"1997","unstructured":"Najean, Y., Rain, J.D., 1997b. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Seminars Hematol., 34(1):6\u201316.","journal-title":"Seminars Hematol."},{"issue":"4","key":"3716_CR93","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF03165029","volume":"8","author":"Y Nakabeppu","year":"1994","unstructured":"Nakabeppu, Y., Nakajo, M., 1994. Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG. Ann. Nucl. Med., 8(4):259\u2013268. [doi:10.1007\/BF03165029]","journal-title":"Ann. Nucl. Med."},{"issue":"5","key":"3716_CR94","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hed.21243","volume":"32","author":"MV Nestor","year":"2010","unstructured":"Nestor, M.V., 2010. Targeted radionuclide therapy in head and neck cancer. Head Neck, 32(5):666\u2013678. [doi:10.1002\/hed.21243]","journal-title":"Head Neck"},{"issue":"12","key":"3716_CR95","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","volume":"11","author":"S Nilsson","year":"2005","unstructured":"Nilsson, S., Larsen, R.H., Fossa, S.D., et al., 2005. First clinical experience with \u03b1-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res., 11(12):4451\u20134459. [doi:10.1158\/1078-0432.CCR-04-2244]","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"3716_CR96","first-page":"492","volume":"32","author":"EE Osgood","year":"1968","unstructured":"Osgood, E.E., 1968. The case for 32P in treatment of polycythemia vera. Blood, 32(3):492\u2013499.","journal-title":"Blood"},{"issue":"3","key":"3716_CR97","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","volume":"55","author":"J Panyam","year":"2003","unstructured":"Panyam, J., Labhasetwar, V., 2003. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 55(3):329\u2013347. [doi:10.1016\/S0169-409X(02)00228-4]","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"3716_CR98","first-page":"189","volume":"36","author":"C Parmentier","year":"1994","unstructured":"Parmentier, C., Gardet, P., 1994. The use of 32 phosphorus (32P) in the treatment of polycythemia vera. Nouvelle Revue Fran\u00e7aise D\u2019h\u00e9matologie, 36(2):189\u2013192.","journal-title":"Nouvelle Revue Fran\u00e7aise D\u2019h\u00e9matologie"},{"issue":"6","key":"3716_CR99","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1227\/01.NEU.0000159649.71890.30","volume":"56","author":"SJ Patel","year":"2005","unstructured":"Patel, S.J., Shapiro, W.R., Laske, D.W., et al., 2005. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery, 56(6):1243\u20131253. [doi:10.1227\/01.NEU.0000159649.71890.30]","journal-title":"Neurosurgery"},{"key":"3716_CR100","doi-asserted-by":"crossref","first-page":"a1577","DOI":"10.1136\/bmj.a1577","volume":"337","author":"A Perkins","year":"2008","unstructured":"Perkins, A., Hilson, A., Hall, J., 2008. Global shortage of medical isotopes threatens nuclear medicine services. BMJ, 337:a1577. [doi:10.1136\/bmj.a1577]","journal-title":"BMJ"},{"issue":"9","key":"3716_CR101","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/MNM.0b013e32832da277","volume":"30","author":"AC Perkins","year":"2009","unstructured":"Perkins, A.C., Vivian, G., 2009. Molybdenum supplies and nuclear medicine services. Nucl. Med. Commun., 30(9): 657\u2013659. [doi:10.1097\/MNM.0b013e32832da27700006231-200909000-00001]","journal-title":"Nucl. Med. Commun."},{"issue":"2","key":"3716_CR102","first-page":"15N","volume":"52","author":"MR Pillai","year":"2011","unstructured":"Pillai, M.R., Knapp, F.F.R.Jr., 2011. Overcoming the 99mTc shortage: are options being overlooked? J. Nucl. Med., 52(2):15N\u201328N.","journal-title":"J. Nucl. Med."},{"issue":"34","key":"3716_CR103","doi-asserted-by":"crossref","first-page":"21769","DOI":"10.1074\/jbc.273.34.21769","volume":"273","author":"A Pini","year":"1998","unstructured":"Pini, A., Viti, F., Santucci, A., et al., 1998. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem., 273(34): 21769\u201321776. [doi:10.1074\/jbc.273.34.21769]","journal-title":"J. Biol. Chem."},{"issue":"10","key":"3716_CR104","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s002590050143","volume":"24","author":"F Pons","year":"1997","unstructured":"Pons, F., Herranz, R., Garcia, A., et al., 1997. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur. J. Nucl. Med., 24(10): 1210\u20131214. [doi:10.1007\/s002590050143]","journal-title":"Eur. J. Nucl. Med."},{"issue":"3","key":"3716_CR105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y","volume":"6","author":"D Pressman","year":"1953","unstructured":"Pressman, D., Korngold, L., 1953. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer, 6(3):619\u2013623. [doi:10.1002\/1097-0142(195305)6:3\u2329619:: AID-CNCR2820060319\u232a3.0.CO;2-Y]","journal-title":"Cancer"},{"issue":"4\u20135","key":"3716_CR106","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1524\/ract.2001.89.4-5.297","volume":"89","author":"SM Qaim","year":"2001","unstructured":"Qaim, S.M., 2001. Therapeutic radionuclides and nuclear data. Radiochim. Acta, 89(4\u20135):297\u2013302. [doi:10.1524\/ract.2001.89.4-5.297]","journal-title":"Radiochim. Acta"},{"key":"3716_CR107","volume-title":"Nulcear data for the production of therapeutic radionuclides","author":"SM Qaim","year":"2011","unstructured":"Qaim, S.M., Tarkanyi, F., Capote, R., 2011. Nulcear data for the production of therapeutic radionuclides. International Atomic Energy Agency, Vienna, Austria."},{"issue":"1","key":"3716_CR108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/1450-1147.113942","volume":"12","author":"N Rasulova","year":"2013","unstructured":"Rasulova, N., Lyubshin, V., Arybzhanov, D., et al., 2013. Effectiveness of bone metastases treatment by Sm-153 oxabifore in combination with monoclonal antibody denosumab (Xgeva): first experience. World J. Nucl. Med., 12(1):19\u201323. [doi:10.4103\/1450-1147.113942]","journal-title":"World J. Nucl. Med."},{"issue":"1","key":"3716_CR109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0969-8043(95)00262-6","volume":"47","author":"BA Rhodes","year":"1996","unstructured":"Rhodes, B.A., Lambert, C.R., Marek, M.J., et al., 1996. Re-188 labelled antibodies. Appl. Radiat. Isot., 47(1): 7\u201314. [doi:10.1016\/0969-8043(95)00262-6]","journal-title":"Appl. Radiat. Isot."},{"issue":"1","key":"3716_CR110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.nano.2006.11.008","volume":"3","author":"SK Sahoo","year":"2007","unstructured":"Sahoo, S.K., Parveen, S., Panda, J.J., 2007. The present and future of nanotechnology in human health care. Nanomed. Nanotechnol. Biol. Med., 3(1):20\u201331. [doi:10.1016\/j.nano.2006.11.008]","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"12","key":"3716_CR111","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/RLU.0b013e3182a7596b","volume":"38","author":"A Sainz-Esteban","year":"2013","unstructured":"Sainz-Esteban, A., Baum, R.P., 2013. Successful treatment of metastasized pancreatic vasoactive intestinal polypeptide-secreting tumor unresponsive to high-dose octreotide by peptide receptor radionuclide therapy using 90Y DOTA TATE. Clin. Nucl. Med., 38(12):996\u2013997. [doi:10.1097\/RLU.0b013e3182a7596b00003072-201312000-00018]","journal-title":"Clin. Nucl. Med."},{"issue":"12","key":"3716_CR112","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.leukres.2009.06.025","volume":"33","author":"C Schliemann","year":"2009","unstructured":"Schliemann, C., Wiedmer, A., Pedretti, M., et al., 2009. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk. Res., 33(12): 1718\u20131722. [doi:10.1016\/j.leukres.2009.06.025]","journal-title":"Leuk. Res."},{"issue":"15","key":"3716_CR113","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.addr.2006.09.020","volume":"58","author":"D Schmaljohann","year":"2006","unstructured":"Schmaljohann, D., 2006. Thermo- and pH-responsive polymers in drug delivery. Adv. Drug Deliv. Rev., 58(15): 1655\u20131670. [doi:10.1016\/j.addr.2006.09.020]","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"S1","key":"3716_CR114","first-page":"48S","volume":"46","author":"P Schneider","year":"2005","unstructured":"Schneider, P., Farahati, J., Reiners, C., 2005. Radiosynovectomy in rheumatology, orthopedics, and hemophilia. J. Nucl. Med., 46(S1):48S\u201354S.","journal-title":"J. Nucl. Med."},{"issue":"4","key":"3716_CR115","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/cbr.2008.0595","volume":"24","author":"CC Schultz","year":"2009","unstructured":"Schultz, C.C., Campbell, J., Bakalyar, D., et al., 2009. Y-90 microsphere therapy: prevention of adverse events. Cancer Biother. Radiopharm., 24(4):427\u2013433. [doi:10.1089\/cbr.2008.0595]","journal-title":"Cancer Biother. Radiopharm."},{"issue":"4","key":"3716_CR116","first-page":"689","volume":"34","author":"G Sgouros","year":"1993","unstructured":"Sgouros, G., 1993. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. Nucl. Med., 34(4):689\u2013694.","journal-title":"J. Nucl. Med."},{"issue":"9","key":"3716_CR117","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/MNM.0b013e32833d6869","volume":"31","author":"SA Shamim","year":"2010","unstructured":"Shamim, S.A., Kumar, R., Halanaik, D., et al., 2010. Role of rhenium-188 tin colloid radiosynovectomy in patients with inflammatory knee joint conditions refractory to conventional therapy. Nucl. Med. Commun., 31(9): 814\u2013820. [doi:10.1097\/MNM.0b013e32833d6869]","journal-title":"Nucl. Med. Commun."},{"issue":"2","key":"3716_CR118","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0001-2998(79)80041-0","volume":"9","author":"EB Silberstein","year":"1979","unstructured":"Silberstein, E.B., 1979. Radionuclide therapy of hematologic disorders. Semin. Nucl. Med., 9(2):100\u2013107.","journal-title":"Semin. Nucl. Med."},{"key":"3716_CR119","volume-title":"Paving the Way to Personalized Medicine: Production of Some Promising Theragnostic Radionuclides at Brookhaven National Laboratory","author":"SC Srivastava","year":"2012","unstructured":"Srivastava, S.C., 2012. Paving the Way to Personalized Medicine: Production of Some Promising Theragnostic Radionuclides at Brookhaven National Laboratory. Seminars in Nuclear Medicine, Elsevier."},{"issue":"4","key":"3716_CR120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/108497802760363213","volume":"17","author":"MG Stabin","year":"2002","unstructured":"Stabin, M.G., Eckerman, K.F., Bolch, W.E., et al., 2002. Evolution and status of bone and marrow dose models. Cancer Biother. Radiopharm., 17(4):427\u2013433. [doi:10.1089\/108497802760363213]","journal-title":"Cancer Biother. Radiopharm."},{"issue":"1","key":"3716_CR121","first-page":"128","volume":"26","author":"S Tavintharan","year":"1997","unstructured":"Tavintharan, S., Sundram, F.X., Chew, L.S., 1997. Radioiodine (I-131) therapy and the incidence of hypothyroidism. Ann. Acad. Med. Singap., 26(1):128\u2013131.","journal-title":"Ann. Acad. Med. Singap."},{"issue":"S1","key":"3716_CR122","first-page":"107S","volume":"46","author":"JJ Teunissen","year":"2005","unstructured":"Teunissen, J.J., Kwekkeboom, D.J., Kooij, P.P., et al., 2005. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J. Nucl. Med., 46(S1):107S\u2013114S.","journal-title":"J. Nucl. Med."},{"issue":"4","key":"3716_CR123","first-page":"351","volume":"35","author":"T Thamboo","year":"2003","unstructured":"Thamboo, T., Tan, K.B., Wang, S.C., et al., 2003. Extra-hepatic embolisation of Y-90 microspheres from selective internal radiation therapy (SIRT) of the liver. Pathology, 35(4):351\u2013353. [doi:10.1080\/0031302031000152892]","journal-title":"Pathology"},{"issue":"2","key":"3716_CR124","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/107327481201900208","volume":"19","author":"M Tomblyn","year":"2012","unstructured":"Tomblyn, M., 2012. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control., 19(2): 137\u2013144.","journal-title":"Cancer Control."},{"issue":"2","key":"3716_CR125","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1148\/radiographics.20.2.g00mc33533","volume":"20","author":"RE Toohey","year":"2000","unstructured":"Toohey, R.E., Stabin, M.G., Watson, E.E., 2000. The AAPM\/RSNA physics tutorial for residents. Internal radiation dosimetry: principles and applications1 (CME available in print version and on RSNA Link). Radiographics, 20(2):533\u2013546. [doi:10.1148\/radiographics.20.2.g00mc33533]","journal-title":"Radiographics"},{"issue":"2","key":"3716_CR126","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","volume":"4","author":"VP Torchilin","year":"2005","unstructured":"Torchilin, V.P., 2005. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 4(2): 145\u2013160. [doi:10.1038\/nrd1632]","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"3716_CR127","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2215\/CJN.11291210","volume":"6","author":"G Tripepi","year":"2011","unstructured":"Tripepi, G., Mattace Raso, F., Sijbrands, E., et al., 2011. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin. J. Am. Soc. Nephrol., 6(7):1714\u20131721. [doi:10.2215\/CJN.11291210]","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"3716_CR128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0883-2897(87)90039-0","volume":"14","author":"DE Troutner","year":"1987","unstructured":"Troutner, D.E., 1987. Chemical and physical properties of radionuclides. Int. J. Radiat. Appl. Instrument. Part B. Nucl. Med. Biol., 14(3):171\u2013176. [doi:10.1016\/0883-2897(87)90039-0]","journal-title":"Int. J. Radiat. Appl. Instrument. Part B. Nucl. Med. Biol."},{"issue":"1","key":"3716_CR129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2516.2006.01406.x","volume":"13","author":"C Turkmen","year":"2007","unstructured":"Turkmen, C., Ozturk, S., Unal, S.N., et al., 2007. Monitoring the genotoxic effects of radiosynovectomy with Re-186 in paediatric age group undergoing therapy for haemophilic synovitis. Haemophilia, 13(1):57\u201364. [doi:10.1111\/j.1365-2516.2006.01406.x]","journal-title":"Haemophilia"},{"issue":"9","key":"3716_CR130","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/MNM.0b013e3283023f9e","volume":"29","author":"O Ugur","year":"2008","unstructured":"Ugur, O., Gedik, G.K., Atilla, B., et al., 2008. Radiosynovectomy: current status in the management of arthritic conditions. Nucl. Med. Commun., 29(9):755\u2013758. [doi:10.1097\/MNM.0b013e3283023f9e]","journal-title":"Nucl. Med. Commun."},{"issue":"2","key":"3716_CR131","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","volume":"36","author":"R Valkema","year":"2006","unstructured":"Valkema, R., Pauwels, S., Kvols, L.K., et al., 2006. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin. Nucl. Med., 36(2):147\u2013156. [doi:10.1053\/j.semnuclmed.2006.01.001]","journal-title":"Semin. Nucl. Med."},{"issue":"4","key":"3716_CR132","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3171\/foc.2006.20.4.8","volume":"20","author":"WA Vandergrift","year":"2006","unstructured":"Vandergrift, W.A., Patel, S.J., 2006. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg. Focus, 20(4):E13. [doi:10.3171\/foc.2006.20.4.8]","journal-title":"Neurosurg. Focus"},{"issue":"4","key":"3716_CR133","first-page":"409","volume":"161","author":"P Streek vande","year":"1994","unstructured":"vande Streek, P., Carretta, R., Weiland, F.L., 1994. Bone pain and radionuclide therapy. West J. Med., 161(4):409.","journal-title":"West J. Med."},{"issue":"11","key":"3716_CR134","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/ijc.23408","volume":"122","author":"A Villa","year":"2008","unstructured":"Villa, A., Trachsel, E., Kaspar, M., et al., 2008. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int. J. Cancer, 122(11): 2405\u20132413. [doi:10.1002\/ijc.23408]","journal-title":"Int. J. Cancer"},{"issue":"1","key":"3716_CR135","first-page":"174","volume":"32","author":"WA Volkert","year":"1991","unstructured":"Volkert, W.A., Goeckeler, W.F., Ehrhardt, G.J., et al., 1991. Therapeutic radionuclides: production and decay property considerations. J. Nucl. Med., 32(1):174\u2013185.","journal-title":"J. Nucl. Med."},{"key":"3716_CR136","volume-title":"MIRD: radionuclide Data and Decay Scheme","author":"D Weber","year":"1989","unstructured":"Weber, D., Eckerman, K., Dillman, L.T., et al., 1989. MIRD: radionuclide Data and Decay Scheme. Society of Nuclear Medicine, New York."},{"issue":"3","key":"3716_CR137","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00063030-200519030-00002","volume":"19","author":"RE Weiner","year":"2005","unstructured":"Weiner, R.E., Thakur, M.L., 2005. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs, 19(3): 145\u2013163. [doi:10.2165\/00063030-200519030-00002]","journal-title":"BioDrugs"},{"issue":"11","key":"3716_CR138","first-page":"783","volume":"33","author":"SC Werner","year":"1957","unstructured":"Werner, S.C., Coelho, B., Quimby, E.H., 1957. Ten year results of I-131 therapy of hyperthyroidism. Bull. N. Y. Acad. Med., 33(11):783\u2013806.","journal-title":"Bull. N. Y. Acad. Med."},{"issue":"7","key":"3716_CR139","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1118\/1.2938520","volume":"35","author":"LE Williams","year":"2008","unstructured":"Williams, L.E., DeNardo, G.L., Meredith, R.F., 2008. Targeted radionuclide therapy. Med. Phys., 35(7):3062\u20133068. [doi:10.1118\/1.2938520]","journal-title":"Med. Phys."},{"issue":"10","key":"3716_CR140","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig, T.E., Gordon, L.I., Cabanillas, F., et al., 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J. Clin. Oncol., 20(10):2453\u20132463. [doi:10.1200\/JCO.2002.11.076]","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"3716_CR141","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00259-012-2145-5","volume":"39","author":"L Wu","year":"2012","unstructured":"Wu, L., Yang, Y.F., Ge, N.J., et al., 2012. Hepatic artery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. Eur. J. Nucl. Med. Mol. Imaging, 39(8):1306\u20131315. [doi:10.1007\/s00259-012-2145-5]","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"3716_CR142","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"JJ Zaknun","year":"2013","unstructured":"Zaknun, J.J., Bodei, L., Mueller-Brand, J., et al., 2013. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 40(5):800\u2013816. [doi:10.1007\/s00259-012-2330-6]","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"10","key":"3716_CR143","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1088\/0031-9155\/41\/10\/004","volume":"41","author":"J Zweit","year":"1996","unstructured":"Zweit, J., 1996. Radionuclides and carrier molecules for therapy. Phys. Med. Biol., 41(10):1905. [doi:10.1088\/0031-9155\/41\/10\/004]","journal-title":"Phys. Med. Biol."}],"container-title":["Journal of Zhejiang University SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1400131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1631\/jzus.B1400131\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1400131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T22:32:42Z","timestamp":1717453962000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1631\/jzus.B1400131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":143,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["3716"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b1400131","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}